<DOC>
	<DOCNO>NCT01588002</DOCNO>
	<brief_summary>This phase 1 , randomize , open-label , multiple-dose , 2-sequence , 2-period crossover study evaluate potential drug-drug interaction efavirenz danoprevir low-dose ritonavir healthy volunteer . In Period 1. subject randomize receive multiple oral dos either danoprevir ritonavir efavirenz 14 day . In Period 2 , subject receive multiple oral dos combination danoprevir ritonavir efavirenz 14 day . Anticipated time study treatment 28 day .</brief_summary>
	<brief_title>A Study Potential Drug-Drug Interaction Between Efavirenz Danoprevir With Low Dose Ritonavir Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Lactams</mesh_term>
	<criteria>Healthy male female nonsmoking subject , 18 55 year age Healthy status define absence evidence active chronic disease follow detailed medical surgical history complete physical examination Medical history without major , recent ongoing pathology Weight &gt; /= 50.0 kg Body mass index ( BMI ) 18.0 32.0 kg/m2 Pregnant lactate woman male female partner pregnant lactate History clinically significant medical condition may impact safety participant Positive result drug abuse screen prior admission clinical site study period Positive hepatitis B , hepatitis C HIV infection Current smoker subject discontinue smoke less 6 month prior first dose study medication Use hormonal contraceptive ( e.g . birth control pill , patch , injectable , implantable device ) within 30 day first dose study medication Use investigational drug device within 30 day first dose study medication ( 6 month biologic therapy ) 5 halflives investigational drug , whichever long History drugrelated allergic reaction History ( within 3 month screen ) alcohol consumption exceed 2 standard drink per day average ; alcohol consumption prohibit 72 hour prior entry clinical site center throughout entire study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>